Purchase
Description
Infliximab biosimilar is a chimeric IgG1κ monoclonal antibody (composed of human constant and murine variable regions) specific for human tumor necrosis factor-alpha (TNFα). It has a molecular weight of approximately 149.1 kilodaltons. Infliximab biosimilar is produced by a recombinant cell line cultured by suspension culture and is purified by a series of steps that includes measures to inactivate and remove viruses.
Infliximab biosimilar is supplied at a concentration of 10 mg/mL as a sterile, clear and colorless, preservative-free liquid of pH approximately 7.2, which contains 0.61 mg/mL dibasic sodium phosphate, dihydrate, 2.2 mg/mL monobasic sodium phosphate, monohydrate, 0.5 mg /mL polysorbate 80, 50 mg/mL sucrose and Water for Injection.
Statement: this product is used for R&D only, not for clinical usage.
Properties
|
Name
|
Infliximab biosimilar
|
|
CAS
NO.
|
170277-31-3
|
|
Type
|
Whole
antibody
|
|
Source
|
Chimeric (mouse/human)
|
|
Target
|
TNF alpha
|
|
Clone
|
Monoclone
|
|
Formula
|
C6428H9912N1694O1987S46
|
|
Molecular
Weight
|
149 kDa
|
|
Antibody
Form
|
Purified immunoglobulin
|
|
Physical
Form
|
Solution
|
|
Grade
Standard
|
Medicine Grade
|
|
Storage
|
-70±15℃ for long-term storage,
2-8℃ for short-term storage, away from light.
|
Supply Ability
20 kilogram per year, Minimum order quantity is 1 gram.
Price
Inquiry
Material Safety Data Sheet
If you need more information, please contact us.
Certificate Of Analysis
/en/UploadFile/file/201805/20180508154279837983.rar
Detail information about the product please refer the website below：
https://en.wikipedia.org/wiki/Infliximab
|
